Virtual Breakfast Series - Emily Minkow & Jason Kent
Emily Minkow and Jason Kent are joining NewYorkBIO for the Virtual Breakfast Series next Tuesday. They will discuss the inner workings of biotech transactions - from venture financing to corporate partnerships to IPOs and everything in between. In addition to her experience at RA Ventures and a wide range of business leadership roles at Celgene, Emily was the Chief Business Officer of Prevail Therapeutics, which was acquired by Eli Lilly for $880MM.
Jason brings a deep perspective from 25 years of counseling biotech clients across the transactional spectrum. He has insights on "open" and "closed" IPO windows and a wide range of transactional markets for both venture financings and partnering deals.
Please use the link below to register and we will see you Tuesday morning at 9:00am!